BRPI0706742B8 - proteína de fusão isolada, homodímero, proteína homodimérica isolada, dímero isolado, sequência de ácido nucleico, polinucleotídeo isolada, molécula de dna recombinante isolada, composição farmacêutica, método para produzir uma proteína, e, uso de uma proteína de fusão e de um dímero - Google Patents

proteína de fusão isolada, homodímero, proteína homodimérica isolada, dímero isolado, sequência de ácido nucleico, polinucleotídeo isolada, molécula de dna recombinante isolada, composição farmacêutica, método para produzir uma proteína, e, uso de uma proteína de fusão e de um dímero Download PDF

Info

Publication number
BRPI0706742B8
BRPI0706742B8 BRPI0706742A BRPI0706742A BRPI0706742B8 BR PI0706742 B8 BRPI0706742 B8 BR PI0706742B8 BR PI0706742 A BRPI0706742 A BR PI0706742A BR PI0706742 A BRPI0706742 A BR PI0706742A BR PI0706742 B8 BRPI0706742 B8 BR PI0706742B8
Authority
BR
Brazil
Prior art keywords
fusion protein
isolated
protein
dimer
nucleic acid
Prior art date
Application number
BRPI0706742A
Other languages
English (en)
Inventor
Wang Haitao
Xu Jing
Liu Longbin
Zhang Rui
Du Yong
Original Assignee
Novagen Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagen Holding Corp filed Critical Novagen Holding Corp
Publication of BRPI0706742A2 publication Critical patent/BRPI0706742A2/pt
Publication of BRPI0706742B1 publication Critical patent/BRPI0706742B1/pt
Publication of BRPI0706742B8 publication Critical patent/BRPI0706742B8/pt
Publication of BRPI0706742C1 publication Critical patent/BRPI0706742C1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

proteina de fusão, construção de proteina dimerica, proteina dimerica, composição farmacêutica, sequencia de ácido nucleico, molécula de dna recombinante, linhagem de células, metodos para produzir uma proteina e para estimular a eritropojese em um mamífero, e, dímero uma proteína de fusão recombinante compreendendo uma porção de peptídeo de eritropoietina humana ligada a uma porção de peptídeo de imunoglobulina é descrita. a proteína de fusão tem uma meia-vida prolongada in vivo em comparação com a eritropoietina humana de ocorrência natural ou nativarecombinante. em uma forma de realização da invenção, a proteína tem uma meia-vida in vivo pelo menos três vezes maior do que a da eritropoietina humana nativa. a proteína de fusão também demonstra uma melhorada bioatividade eritropoiética em comparação com a eritropoietina humana nativa. em uma forma de realização, a proteína de fusão compreende a seqúência de peptídeo completade uma molécula de eritropoietina humana (epo) e a seqúência de peptídeo de um fragmento fc de imunoglobulina humana igg 1. o fragmento fc na proteína de fusão inclui a região de articulação, domínios ch2 e c113 de imunoglobulina humana iggl. a molécula de epo pode estar ligada diretamente ao fragmento fe para evitar ligadores de peptídeo estranhos e diminuir o risco de uma resposta imunogênica quando administrada in vivo. em uma forma de realização, a regiãode articulação é uma variante do fragmento fc humano tendo um resíduo não cisteína em aminoácido 6. a invenção também refere-se às seqúências de ácido nucleico e aminoácido codificando a proteína de fusão e linhagens de células transfectadas e métodos para produzir a proteína de fusão. a invenção ainda inclui composições farmacêuticas compreendendo a proteína de fusão e métodos de usar a proteína de fusão e/ou as composições farmacêuticas, por exemplo para estimular a eritropoiese em indivíduos em necessidade de terapia.
BRPI0706742A 2006-01-27 2007-01-25 proteína de fusão isolada, homodímero, proteína homodimérica isolada, dímero isolado, sequência de ácido nucleico, polinucleotídeo isolada, molécula de dna recombinante isolada, composição farmacêutica, método para produzir uma proteína, e, uso de uma proteína de fusão e de um dímero BRPI0706742C1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/340,661 US7625564B2 (en) 2006-01-27 2006-01-27 Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
US11/340,661 2006-01-27
PCT/CA2007/000107 WO2007085084A1 (en) 2006-01-27 2007-01-25 Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo

Publications (4)

Publication Number Publication Date
BRPI0706742A2 BRPI0706742A2 (pt) 2011-04-05
BRPI0706742B1 BRPI0706742B1 (pt) 2019-12-03
BRPI0706742B8 true BRPI0706742B8 (pt) 2019-12-24
BRPI0706742C1 BRPI0706742C1 (pt) 2021-05-25

Family

ID=38308802

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706742A BRPI0706742C1 (pt) 2006-01-27 2007-01-25 proteína de fusão isolada, homodímero, proteína homodimérica isolada, dímero isolado, sequência de ácido nucleico, polinucleotídeo isolada, molécula de dna recombinante isolada, composição farmacêutica, método para produzir uma proteína, e, uso de uma proteína de fusão e de um dímero

Country Status (20)

Country Link
US (8) US7625564B2 (pt)
EP (2) EP2450373B1 (pt)
JP (3) JP5222153B2 (pt)
KR (2) KR20120014936A (pt)
CN (3) CN102516399B (pt)
AU (1) AU2007209722B2 (pt)
BR (1) BRPI0706742C1 (pt)
CA (1) CA2650072C (pt)
DK (2) DK1994157T3 (pt)
ES (2) ES2539778T3 (pt)
IL (1) IL192801A (pt)
MX (1) MX2008009322A (pt)
NZ (1) NZ569702A (pt)
PL (2) PL2450373T3 (pt)
PT (2) PT2450373E (pt)
RU (1) RU2433181C2 (pt)
SG (2) SG10201404308RA (pt)
TW (1) TWI454482B (pt)
WO (1) WO2007085084A1 (pt)
ZA (1) ZA200805920B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2559228C (en) 2004-04-21 2016-06-21 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
JP4356902B2 (ja) * 2006-12-28 2009-11-04 信広 益子 歯ブラシ
BRPI0814465B1 (pt) * 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP2012518408A (ja) 2009-02-24 2012-08-16 アレクシオン ファーマシューティカルズ， インコーポレイテッド 治療用ｔｐｏ／ｅｐｏ模倣ペプチドを含む抗体
US20110016548A1 (en) * 2009-07-16 2011-01-20 University Of Southern California Control of endogenous dnmt1 gene expression by exogenous binary regulatory systems
BR112012027765A2 (pt) 2010-04-30 2019-09-24 Enobia Pharma Inc. métodos, composições e kits para tratamento de distúrbios de mineralização da matriz.
CN102260343A (zh) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 重组人g-csf二聚体在治疗神经损伤疾病中的用途
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
KR102231139B1 (ko) 2011-06-28 2021-03-24 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
CN103732240B (zh) 2011-07-25 2015-12-09 健能隆医药技术（上海）有限公司 G-csf二聚体在制备治疗神经退行性疾病药物中的应用
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
WO2013027191A1 (en) * 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
KR101183615B1 (ko) * 2011-12-28 2012-09-17 재단법인 경기과학기술진흥원 Ｗｎｔ에 결합하는 신규한 재조합 단백질
JP5836402B2 (ja) * 2012-01-25 2015-12-24 Ｓｂｉファーマ株式会社 腫瘍診断剤
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015533483A (ja) * 2012-09-07 2015-11-26 サノフイ メタボリックシンドロームを治療するための融合タンパク質
WO2014093387A1 (en) * 2012-12-10 2014-06-19 Kindred Biosciences, Inc. Vegf receptor fusion proteins for veterinary use
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
RU2563175C1 (ru) * 2014-06-03 2015-09-20 государственное бюджетное образовательное учреждение высшего профессионального образования "Тюменская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТюмГМА Минздрава России) Способ стимуляции эритропоэза в предоперационном периоде
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
EP3194429A4 (en) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Novel feline erythropoietin receptor agonists
MX389350B (es) 2014-12-05 2025-03-19 Alexion Pharma Inc Fosfatasas alcalinas recombinantes y usos de las mismas para el tratamiento de convulsiones.
JP6559241B2 (ja) * 2015-01-09 2019-08-14 ジェネクシン, インク.Genexine, Inc. 持続型ｅｐｏ製剤を用いた貧血治療方法
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
WO2016178087A1 (en) 2015-05-04 2016-11-10 Biosourcing Sa Transgenic production of chorionic gonadotropin
WO2016178089A1 (en) 2015-05-04 2016-11-10 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Transgenic production of fc fusion proteins
CN108350440A (zh) 2015-08-17 2018-07-31 阿雷克森制药公司 碱性磷酸酯的制造
JP6868617B2 (ja) 2015-09-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 低ホスファターゼ血症の組織非特異的アルカリホスファターゼ（ｔｎｓａｌｐ）酵素補充療法に有効な投薬計画の特定
CN105111315B (zh) * 2015-09-29 2018-05-22 海南医学院 MIP3α-Fc融合蛋白及其用途
US12048753B2 (en) 2015-10-01 2024-07-30 Whitehead Institute For Biomedical Research Labeling of antibodies
KR101847169B1 (ko) * 2015-10-07 2018-04-09 주식회사 녹십자 지속형 에리트로포이에틴 함유 조성물
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
CN114835793A (zh) * 2015-11-16 2022-08-02 Ubi蛋白公司 用于延长蛋白质半衰期的方法
WO2017155569A1 (en) 2016-03-08 2017-09-14 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
JP7613826B2 (ja) 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
JP2019536823A (ja) * 2016-12-05 2019-12-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫反応が弱化された結合体
EP3600383A4 (en) 2017-03-31 2020-10-28 Alexion Pharmaceuticals, Inc. METHODS OF TREATMENT OF HYPOPHOSPHATASIA (HPP) IN ADULTS AND ADOLESCENTS
WO2018203582A1 (ko) * 2017-05-05 2018-11-08 주식회사 유비프로틴 단백질 반감기를 증가시키는 방법
CN110078817B (zh) * 2018-01-26 2021-02-19 重庆精准生物技术有限公司 一种改良的铰链区及其在构建car骨架中的应用
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
WO2020053661A1 (en) 2018-09-13 2020-03-19 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Methods of purifying antibodies from the milk of transgenic non-human mammals comprising the use of chitosan
RU2696864C1 (ru) * 2018-09-24 2019-08-07 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений микроциркуляции в почках асиалированным эритропоэтином в эксперименте
RU2678768C1 (ru) * 2018-09-25 2019-02-01 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
JP7796415B2 (ja) * 2020-06-10 2026-01-09 株式会社バイカ・セラピュティクス エリスロポエチンポリペプチドを含む融合タンパク質
US20230265407A1 (en) * 2020-07-02 2023-08-24 Northwestern University Human recombinant ace2-fc mutants that decouple anti-sars-cov-2 activity from cardiovascular effects
CN111704676A (zh) * 2020-07-17 2020-09-25 上海延立药业有限公司 一种长效重组促红细胞生成素及其制备方法和应用
AU2021337652B2 (en) 2020-09-04 2025-01-30 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
WO2022080912A1 (ko) * 2020-10-16 2022-04-21 주식회사 아이엠바이오로직스 IgM 영역을 이용한 융합단백질 플랫폼
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US7253264B1 (en) * 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
DE69534265T2 (de) * 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US6096871A (en) * 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6277375B1 (en) * 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
AU8182298A (en) 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
EP1088888A4 (en) 1998-05-14 2005-03-16 Merck Patent Gmbh MERGED PROTEIN
DE69933216T2 (de) 1998-06-15 2007-09-20 GTC Biotherapeutics, Inc., Framingham Erythropoietin-analog-menschliches serum-albumin fusionsprotein
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7754855B1 (en) 1999-07-13 2010-07-13 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
AU1226901A (en) 1999-10-22 2001-05-08 Amgen, Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
CA2391080A1 (en) * 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
PT1274728E (pt) 2000-04-21 2008-06-20 Amgen Inc Métodos e composições para a prevenção e tratamento de anemia
EP1342730B1 (en) 2000-12-11 2006-03-15 Cheil Jedang Corporation Fusion protein having the enhanced in vivo activity of erythropoietin
RU2420537C2 (ru) * 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN100522242C (zh) * 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
KR100467750B1 (ko) 2001-11-29 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
KR100467751B1 (ko) 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US20040063912A1 (en) * 2002-03-15 2004-04-01 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
JP2005526769A (ja) * 2002-03-15 2005-09-08 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 治療剤を全身搬送するための中央気道投与
DE10227606B3 (de) 2002-06-20 2004-01-22 Bionethos Holding Gmbh Verwendung von Thrombopoietin zur Kultivierung von Hepatozyten
WO2004004798A2 (en) 2002-07-03 2004-01-15 The Brigham And Women's Hospital, Inc. Central airway administration for systemic delivery of therapeutics
WO2004042017A2 (en) * 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) * 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
DE602004017726D1 (de) * 2003-06-30 2008-12-24 Domantis Ltd Pegylierte Single-domain-antikörper (dAb)
AU2004273791A1 (en) * 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
WO2006079169A1 (en) 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
WO2007060213A2 (en) * 2005-11-24 2007-05-31 Laboratoires Serono S.A. Erythropoietin polypeptides and uses thereof
US7625564B2 (en) * 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
BRPI0814465B1 (pt) * 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica

Also Published As

Publication number Publication date
CN102516399A (zh) 2012-06-27
JP2016006116A (ja) 2016-01-14
CN101321870B (zh) 2012-07-04
US7964375B2 (en) 2011-06-21
KR20080109739A (ko) 2008-12-17
PL2450373T3 (pl) 2015-08-31
CA2650072C (en) 2015-11-24
JP2009524415A (ja) 2009-07-02
EP2450373A3 (en) 2012-09-26
HK1170507A1 (en) 2013-03-01
TWI454482B (zh) 2014-10-01
EP1994157A1 (en) 2008-11-26
US20230265143A1 (en) 2023-08-24
HK1125673A1 (en) 2009-08-14
US20070178112A1 (en) 2007-08-02
EP1994157A4 (en) 2009-11-11
US11279742B2 (en) 2022-03-22
SG10201404308RA (en) 2014-10-30
RU2008134389A (ru) 2010-03-10
ZA200805920B (en) 2009-08-26
US9375487B2 (en) 2016-06-28
IL192801A0 (en) 2009-02-11
BRPI0706742C1 (pt) 2021-05-25
EP2450373B1 (en) 2015-03-18
ES2539778T3 (es) 2015-07-06
CA2650072A1 (en) 2007-08-02
CN102816242A (zh) 2012-12-12
PT1994157E (pt) 2015-07-22
RU2433181C2 (ru) 2011-11-10
KR20120014936A (ko) 2012-02-20
DK1994157T3 (da) 2015-06-22
DK2450373T3 (da) 2015-06-22
AU2007209722B2 (en) 2012-07-26
EP2450373A2 (en) 2012-05-09
US20100098716A1 (en) 2010-04-22
KR101235124B1 (ko) 2013-03-07
US20130224198A1 (en) 2013-08-29
PL1994157T3 (pl) 2015-08-31
TW200904829A (en) 2009-02-01
NZ569702A (en) 2012-03-30
JP6103579B2 (ja) 2017-03-29
US20100099145A1 (en) 2010-04-22
CN102516399B (zh) 2017-03-22
MX2008009322A (es) 2008-10-17
US10233223B2 (en) 2019-03-19
US7625564B2 (en) 2009-12-01
BRPI0706742A2 (pt) 2011-04-05
ES2539759T3 (es) 2015-07-03
EP1994157B1 (en) 2015-03-18
AU2007209722A1 (en) 2007-08-02
US20190070307A1 (en) 2019-03-07
JP2013066477A (ja) 2013-04-18
JP5222153B2 (ja) 2013-06-26
IL192801A (en) 2016-05-31
US8431132B2 (en) 2013-04-30
US20090297522A1 (en) 2009-12-03
PT2450373E (pt) 2015-07-27
US20170114110A1 (en) 2017-04-27
BRPI0706742B1 (pt) 2019-12-03
SG169351A1 (en) 2011-03-30
CN101321870A (zh) 2008-12-10
US10117949B2 (en) 2018-11-06
WO2007085084A1 (en) 2007-08-02
CN102816242B (zh) 2017-10-20

Similar Documents

Publication Publication Date Title
BRPI0706742B8 (pt) proteína de fusão isolada, homodímero, proteína homodimérica isolada, dímero isolado, sequência de ácido nucleico, polinucleotídeo isolada, molécula de dna recombinante isolada, composição farmacêutica, método para produzir uma proteína, e, uso de uma proteína de fusão e de um dímero
AU2019200797B2 (en) Follistatin in treating duchenne muscular dystrophy
ES3035658T3 (en) Long-acting fgf21 fusion proteins and pharmaceutical composition comprising same
US9956264B2 (en) MIC-1 fusion proteins and uses thereof
US10323075B2 (en) Compositions and methods of use for treating metabolic disorders
US9827291B2 (en) Compositions and methods of use for treating metabolic disorders
EP1362062A4 (en) CONCATAMERE IMMUNADHÄSION
ES2155821T5 (es) Toxinas quimericas mejoradas.
US20170334971A1 (en) Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof
Liu et al. The impact of sialic acids on the pharmacokinetics of a PEGylated erythropoietin
KR102725896B1 (ko) 액티빈/bmp7 키메라: 슈퍼-활성 sab704 및 sab715, 및 이들의 노긴-감작 변이체인 nab704, nab715 및 nab204
EP2948164B1 (en) Placenta growth factor in treating duchenne muscular dystrophy
US10434188B1 (en) Hyaluronic acid binding domain-growth factor fusion protein cDNAs and fusion proteins for cartilage matrix preservation and repair
MY157907A (en) Recombinant human epo-fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
KR20170098940A (ko) 개선된 골형성 단백질
CN112770766A (zh) 经修饰的人促红细胞生成素
ES2337455T3 (es) Constructos de fusion, que contienen secciones activas de ligandos tnf.
AU2017200239A1 (en) Designer osteogenic proteins
HK1217637B (en) Follistatin in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/505 (2006.01), A61K 9/00 (2006.01), A61K 4

B15K Others concerning applications: alteration of classification

Ipc: C12N 15/62 (2006.01), C12N 15/13 (2006.01), C12N 1

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/12/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2552 DE 03/12/2019 QUANTO AO ENDERECO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF